NO20041520L - Farmasoytiske formuleringer for kontrollert frigjoring av 4-amino-6,7-dimetoksy-2- (5-metansulfonamido-1,2,3,4-tetrahydroisokinol-2-yl) -5- (2-pyridyl) kinazolin. - Google Patents

Farmasoytiske formuleringer for kontrollert frigjoring av 4-amino-6,7-dimetoksy-2- (5-metansulfonamido-1,2,3,4-tetrahydroisokinol-2-yl) -5- (2-pyridyl) kinazolin.

Info

Publication number
NO20041520L
NO20041520L NO20041520A NO20041520A NO20041520L NO 20041520 L NO20041520 L NO 20041520L NO 20041520 A NO20041520 A NO 20041520A NO 20041520 A NO20041520 A NO 20041520A NO 20041520 L NO20041520 L NO 20041520L
Authority
NO
Norway
Prior art keywords
tetrahydroisoquinol
methanesulfonamido
quinazoline
dimethoxy
pyridyl
Prior art date
Application number
NO20041520A
Other languages
English (en)
Inventor
Ross James Macrae
Michael John Humphrey
Janet Sarah Smith
John Douglas David
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NO20041520L publication Critical patent/NO20041520L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO20041520A 2001-10-11 2004-04-05 Farmasoytiske formuleringer for kontrollert frigjoring av 4-amino-6,7-dimetoksy-2- (5-metansulfonamido-1,2,3,4-tetrahydroisokinol-2-yl) -5- (2-pyridyl) kinazolin. NO20041520L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0124455.7A GB0124455D0 (en) 2001-10-11 2001-10-11 Pharmaceutical formulations
PCT/IB2002/004040 WO2003032956A1 (en) 2001-10-11 2002-09-30 Pharmaceutical formulations for the controlled release of 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl) quinazoline

Publications (1)

Publication Number Publication Date
NO20041520L true NO20041520L (no) 2004-04-05

Family

ID=9923660

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20041520A NO20041520L (no) 2001-10-11 2004-04-05 Farmasoytiske formuleringer for kontrollert frigjoring av 4-amino-6,7-dimetoksy-2- (5-metansulfonamido-1,2,3,4-tetrahydroisokinol-2-yl) -5- (2-pyridyl) kinazolin.

Country Status (32)

Country Link
EP (1) EP1434570B8 (no)
JP (1) JP4131471B2 (no)
KR (1) KR20050032510A (no)
CN (1) CN1568180A (no)
AP (1) AP2004003001A0 (no)
AR (1) AR036782A1 (no)
AT (1) ATE303135T1 (no)
BR (1) BR0213196A (no)
CA (1) CA2461168A1 (no)
CO (1) CO5560534A2 (no)
DE (1) DE60205925T2 (no)
DK (1) DK1434570T3 (no)
DO (1) DOP2002000464A (no)
EA (1) EA006168B1 (no)
ES (1) ES2246017T3 (no)
GB (1) GB0124455D0 (no)
GT (1) GT200200184A (no)
HR (1) HRP20040261A2 (no)
HU (1) HUP0600064A3 (no)
IL (1) IL160969A0 (no)
IS (1) IS7179A (no)
MA (1) MA27075A1 (no)
MX (1) MXPA04003293A (no)
NO (1) NO20041520L (no)
OA (1) OA12709A (no)
PA (1) PA8556001A1 (no)
PE (1) PE20030551A1 (no)
PL (1) PL369666A1 (no)
SV (1) SV2004001279A (no)
UY (1) UY27477A1 (no)
WO (1) WO2003032956A1 (no)
ZA (1) ZA200401976B (no)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0317663D0 (en) * 2003-07-29 2003-09-03 Astrazeneca Ab Pharmaceutical composition
EA031185B1 (ru) 2013-03-14 2018-11-30 Эмджен Инк. Гетероциклические соединения и способы их применения
KR101943592B1 (ko) 2017-08-31 2019-01-30 조현우 데이터 마이닝 기법을 이용한 전자가계부 시스템

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69008526T2 (de) * 1990-07-02 1994-08-18 Bend Res Inc Asymmetrische mikroporöse Kügelchen für regulierbare Freigabe.
FR2752737B1 (fr) * 1996-08-29 1998-10-02 Synthelabo Comprime a liberation controlee de chlorhydrate d'alfuzosine
GB9700504D0 (en) * 1997-01-11 1997-02-26 Pfizer Ltd Pharmaceutical compounds
IL141235A (en) * 2000-02-09 2012-04-30 Novartis Int Pharm Ltd Combined use of an alpha-adrenoceptor antagonist and a muscarinic antagonist in the preparation of a drug for the treatment of non-malignant prostatic hyperplasia
PT1268468E (pt) * 2000-03-03 2004-01-30 Pfizer Mesilato de 4-amino-6,7dimetoxi-2- (5-metanossulfonamido-1,2,3,4-tetra-hidro-2-isoquinolil)5-5(2-piridil-quinazolina e polimorfos

Also Published As

Publication number Publication date
WO2003032956A1 (en) 2003-04-24
UY27477A1 (es) 2003-05-30
PL369666A1 (en) 2005-05-02
MA27075A1 (fr) 2004-12-20
AR036782A1 (es) 2004-10-06
JP2005507909A (ja) 2005-03-24
PE20030551A1 (es) 2003-06-26
SV2004001279A (es) 2004-02-19
GT200200184A (es) 2003-05-23
ATE303135T1 (de) 2005-09-15
EP1434570B1 (en) 2005-08-31
IL160969A0 (en) 2004-08-31
CA2461168A1 (en) 2003-04-24
HRP20040261A2 (en) 2004-08-31
IS7179A (is) 2004-03-11
EA200400431A1 (ru) 2004-08-26
DK1434570T3 (da) 2005-11-07
DE60205925D1 (de) 2005-10-06
AP2004003001A0 (en) 2004-03-31
HUP0600064A3 (en) 2007-02-28
PA8556001A1 (es) 2003-07-28
JP4131471B2 (ja) 2008-08-13
MXPA04003293A (es) 2004-07-23
EP1434570A1 (en) 2004-07-07
HUP0600064A2 (en) 2006-06-28
CO5560534A2 (es) 2005-09-30
CN1568180A (zh) 2005-01-19
EA006168B1 (ru) 2005-10-27
OA12709A (en) 2006-06-26
ES2246017T3 (es) 2006-02-01
BR0213196A (pt) 2004-08-31
ZA200401976B (en) 2004-07-12
KR20050032510A (ko) 2005-04-07
GB0124455D0 (en) 2001-12-05
DOP2002000464A (es) 2003-04-15
DE60205925T2 (de) 2006-06-08
EP1434570B8 (en) 2005-10-26

Similar Documents

Publication Publication Date Title
IS2399B (is) Aðferðir til að framleiða 2-(N-metýl-N-metansúlfónýlamínó)pýrimidín, hýdroxýpýrimidín, halógenpýrimidín eða lífrænar súlfónýloxýpýrimidín afleiður ogefnasambönd sem fást með þeim
DK1292594T3 (da) Quinazolinderivater til behandling af tumorer
EE200200201A (et) Trüosiinkinaasi pärssiv ühend, seda sisaldav farmatseutiline kompositsioon ning raviotstarbeline kasutamine.
DE60218458D1 (de) Isochinolinon derivate als parp inhibitoren
DK1448235T3 (da) Orale, farmaceutiske sammensætninger af 5,8,14-triaza-tetracyclo[10.3.1.0(2,11).0(4.9)]-hexadeca-2(11),3,5,7,9-pentaen med kontrolleret frigivelse
DK1345910T3 (da) Quinazolinderivater, lægemidler indeholdende forbindelserne, deres anvendelse og fremgangsmåde til fremstilling deraf
DK1341774T3 (da) Kondenserede heteroaromatiske glucokinase-aktivatorer
IS6524A (is) 5-alkýlpyrídó(3-3-D)pyrimídín týrósín kínasa tálmar
DZ3425A1 (fr) Derives de quinolinone en tant qu'inhibiteurs kinases de tyrosine
IS6957A (is) Tatrat sölt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9,-pentaen og lyfjafræðilegar samsetningar af þeim
DK1377556T3 (da) Pyrazolderivater til behandling af HIV
DK1480983T3 (da) Heteroarylsubstituerede 2-pyridinyl- og 2-pyrimidinyl- 6,7,8,9-tetrahydropyrimido[1,2a]pyrimidin-4-onderivater
ATE320256T1 (de) Succinate des 5,8,14-triazatetracyclo(10.3.1.0 2, 11 .0 4,9 )-hexadeca-2(11),3,5,7,9,-pentaens und pharmazeutische zusammensetzungen
IS6956A (is) Sítrat salt af 5,8,14,-tríasatetrasýkló[10.3.1.02,11.04,9]-hexadeka-2(11),3,5,7,9-pentaen og lyfjafræðilegar samsetningar af því
HRP20030695B1 (en) Process for the preparation of imidazole compounds
HUP0300006A3 (en) 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline mesylat and polymorphs, process for their preparation and pharmaceutical compositions containing them
NO20041520L (no) Farmasoytiske formuleringer for kontrollert frigjoring av 4-amino-6,7-dimetoksy-2- (5-metansulfonamido-1,2,3,4-tetrahydroisokinol-2-yl) -5- (2-pyridyl) kinazolin.
NO20053431D0 (no) Ny krystallinsk modifikasjon av 2-(3,5-bis-trifluormetyl-fenyl)-N-(6-(1,1-diokso-1gamma6-tiomorfolin-4-yl)-4(4-fluor-2-metyl-fenyl)-pyridin-3-yl)-N-metyl-isobutyramid.
SE0001373D0 (sv) NPY Y1 receptor agonists and antagonists
HK1062683A1 (en) Synthesis of 4-(piperidyl) (2-pyridyl)methanone-(E)-=-methyloxime and its salts.
DK1345605T3 (da) Varmformet lægemiddelsammensætning til styret afgivelse af perindopril
AU2002256260A1 (en) Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas